Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

United Therapeutics Corporation (UTHR) had Revenue of $2.88B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$2.88B
Net Income	$1.20B
Cost of Goods Sold	$309.70M
Gross Profit	$2.57B
Operating Expenses	$1.50B
Operating Income	$1.38B
Non-Operating Income/Expense	$162.00M
Pre-Tax Income	$1.54B
Normalized Pre-Tax Income	$1.54B
Income after Taxes	$1.20B
Income from Continuous Operations	$1.20B
Consolidated Net Income/Loss	$1.20B
Normalized Income after Taxes	$1.20B
EBIT	$1.38B
EBITDA	$1.45B
Weighted-Average Shares Outstanding (Basic)	45.20M
Weighted-Average Shares Outstanding (Diluted)	48.50M
Earnings per Share (EPS) (Basic)	$26.44
Earnings per Share (EPS) (Diluted)	$24.64
Balance Sheet Financials
Current Assets	$3.87B
Property, Plant, and Equipment	$1.22B
Long-Term Assets	$3.49B
Total Assets	$7.36B
Current Liabilities	$738.10M
Long-Term Debt	--
Long-Term Liabilities	$181.90M
Total Liabilities	$920.00M
Common Equity	$6.44B
Tangible Shareholders Equity	$6.33B
Shareholders Equity	$6.44B
Common Shares Outstanding	44.83M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.33B
Cash Flow from Investing Activities	$417.20M
Cash Flow from Financial Activities	$-1.25B
Beginning Cash	$1.21B
End Cash	$1.70B
Increase/Decrease in Cash	$489.50M
Stock-Based Compensation	$144.00M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.25
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	0.05
Gross Margin	89.24%
Operating Margin	47.86%
EBIT Margin	47.86%
EBITDA Margin	50.38%
Pre-Tax Profit Margin	53.49%
Profit Margin	41.53%
Free Cash Flow	$1.08B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.39
Inventory Turnover	1.96
Receiveable Turnover	10.30
Days Sales in Receivables	35.43
Return on Equity	18.55%
Return on Tangible Equity	18.87%
Return on Assets	16.23%
Return on Investments	18.55%
Book Value Per Share	$143.74
Free Cash Flow per Share	$22.28
Operating Cash Flow per Share	$27.36

Data from Zacks Investment Research, Inc.